Raytel gets class action lawsuit:
This article was originally published in Clinica
Executive Summary
Members of Raytel's board, together with the company, have been named in a class action lawsuit alleging the company's proposed $31 million merger with SHL Telemedicine represents a breach of fiduciary duties of loyalty, good faith and independence. The company announced the proposed deal last month, with SHL offering to buy all Raytel shares for $10.25 per share. Raytel believes the lawsuit lacks merit and plans to defend itself vigorously.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.